NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today the appointment of Dr. Peng Wang as Chief Scientific Officer.
Dr. Wang will lead the company’s R&D team in developing new products and innovative research projects. He will also participate in the strategic planning of the R&D department and manage domestic and international research collaborations.
Dr. Wang has two decades of experience in pharmaceutical R&D, most recently serving as Vice President of Discovery Biology at WuXi PharmaTech. Previously, Dr. Wang was a Research Fellow at Schering-Plough Research Institute where he worked for eighteen years with increasing responsibilities. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo in 1990.
“As a recognized biopharmaceutical expert, Dr. Wang is well positioned to contribute to Simcere’s strategic development in this area,” commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, “Simcere is committed to investing in research and development to support our long term growth, and we are delighted that Dr. Wang has agreed to join us.”
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
CONTACT: For investor and media inquiries, please contact: ir@simcere.com;
Or In Nanjing: Frank Zhigang Zhao, Chief Financial Officer of Simcere
Pharmaceutical Group, +86-25-8556-6666 x8818; Or In Beijing: Kejia Wu of
Brunswick Group, +86-10-6566-2256; In Hong Kong: Joseph Lo Chi-Lun of
Brunswick Group, +852-3512-5000; Or In New York: Kate Tellier of Brunswick
Group LLC, +1-212-333-3810
Web site: http://www.simcere.com/
